Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Antonella Pietragalla"'
Autor:
Domenica Lorusso, Valentina Ceni, Gennaro Daniele, Antonella Pietragalla, Vanda Salutari, Margherita Muratore, Camilla Nero, Francesca Ciccarone, Giovanni Scambia
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 2, Iss 1, Pp 48-64 (2021)
Immunotherapy has changed the natural history of several malignancies that, a decade ago, had a very poor prognosis, such as lung cancer and melanoma. Consequently, many attempts have been done to expand the indications of immunotherapy agents, predo
Externí odkaz:
https://doaj.org/article/f2df47e6aecd4eea87f02cf9e94bbfb3
Autor:
Antonella Pietragalla, Francesca Ciccarone, Camilla Nero, Giovanni Scambia, Domenica Lorusso, Gennaro Daniele
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 1, Iss 3, Pp 171-182 (2020)
Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has cha
Externí odkaz:
https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e
Autor:
Camilla Nero, Francesca Ciccarone, Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Giovanni Scambia, Domenica Lorusso
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Adjuvant therapy recommendations for endometrial cancer were historically based on the individual patient’s risk of disease recurrence using clinicopathologic factors such as age, stage, histologic subtype, tumor grade, and lymphovascular space inv
Externí odkaz:
https://doaj.org/article/e64346d5cfe641f7b343f61782d72f6a
Autor:
Rosa Falcone, Pasquale Lombardi, Marco Filetti, Simona Duranti, Antonella Pietragalla, Alessandra Fabi, Domenica Lorusso, Valeria Altamura, Francesco Paroni Sterbini, Giovanni Scambia, Gennaro Daniele
Publikováno v:
Cancers; Volume 14; Issue 4; Pages: 889
(1) Background: Drug development in oncology is changing rapidly. The aim of the present study was to provide an insight into the features of anti-tumor drugs approved in Europe; (2) Methods: We included all the indications for solid tumors issued by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d78e6a8fb1fb391741c731898cc4a80
http://hdl.handle.net/11573/1620380
http://hdl.handle.net/11573/1620380
Autor:
Elisa De Paolis, Alessia Perrucci, Claudia Marchetti, Antonella Pietragalla, Giovanni Scambia, Andrea Urbani, Anna Fagotti, Angelo Minucci
ObjectiveBRCA1/2 (BRCA) genetic testing allows patients with high-grade serous ovarian cancer to receive appropriate medical management with molecular target therapy and prevention strategies. Most of theBRCAsequencing methods use blood as the primar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01b3cf56b3273571670b58563fba7ac6
https://hdl.handle.net/10807/219711
https://hdl.handle.net/10807/219711
Autor:
Vanda Salutari, Giovanni Scambia, Antonella Pietragalla, Anna Fagotti, Riccardo Tudisco, Claudia Marchetti
Publikováno v:
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 31(8)
BackgroundNeoadjuvant chemotherapy with interval debulking surgery represents an alternative treatment for advanced ovarian cancer. Currently, there are few data about the use of poly adenosine diphosphate-ribose polymerase inhibitors in the neoadjuv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acf9f650706ac4a23e5970a177636cd5
https://pubmed.ncbi.nlm.nih.gov/34131041
https://pubmed.ncbi.nlm.nih.gov/34131041
Autor:
Camilla Nero, Simona Duranti, Giovanni Scambia, Antonella Pietragalla, Domenica Lorusso, Gennaro Daniele, Francesca Ciccarone
Publikováno v:
Cancers, Vol 13, Iss 2089, p 2089 (2021)
Cancers
Cancers
Simple Summary Cervical cancer represents one of the main leading causes of cancer-related mortality in women worldwide. In contrast to patients with early-stage disease, those with advanced, recurrent, or metastatic cervical cancer have a poor progn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ef57aae6a2c9ecf004d050c9e99eaa0
https://www.mdpi.com/2072-6694/13/9/2089
https://www.mdpi.com/2072-6694/13/9/2089
Autor:
Vincenzo Valentini, Giovanni Scambia, Roberto Bernabei, Anna Picca, Franziska Michaela Lohmeyer, Riccardo Calvani, Marika D’Oria, Luca Boldrini, Antonella Pietragalla, Gennaro Daniele, Alfredo Cesario, Domenica Lorusso, Charles Auffray
Publikováno v:
Journal of Personalized Medicine
Journal of Personalized Medicine, Vol 11, Iss 314, p 314 (2021)
Journal of Personalized Medicine, Vol 11, Iss 314, p 314 (2021)
Traditional healthcare paradigms rely on the disease-centered approach aiming at reducing human nature by discovering specific drivers and biomarkers that cause the advent and progression of diseases. This reductive approach is not always suitable to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dde07e3027158a7e1ef3b75b0b88fc6
http://europepmc.org/articles/PMC8074144
http://europepmc.org/articles/PMC8074144
Autor:
Giovanni Scambia, Alessandra Fabi, Riccardo Masetti, Gianluca Franceschini, Fabio Marazzi, Ida Paris, Antonella Pietragalla, Vittoria Barberi, Francesco Cognetti
Publikováno v:
Journal of Personalized Medicine, Vol 11, Iss 532, p 532 (2021)
Journal of Personalized Medicine
Journal of Personalized Medicine
Breast cancer (BC) is the most frequent cancer among women and represents the second leading cause of cancer-specific death. A subset of patients with metastatic breast cancer (MBC) presents limited disease, termed ‘oligometastatic’ breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a53536effac22439c29b4a9534ceef46
https://pubmed.ncbi.nlm.nih.gov/34207648
https://pubmed.ncbi.nlm.nih.gov/34207648
Autor:
Domenica Lorusso, Giovanni Scambia, Antonella Pietragalla, Anna Fagotti, Gennaro Daniele, Francesca Ciccarone, Camilla Nero, Simona Duranti
Publikováno v:
Expert opinion on investigational drugs. 30(2)
Introduction: Ovarian cancer (OC) represents the leading cause of death among gynecological cancers. Despite novel compound classes like vascular endothelial growth factor (VEGF) inhibitors or poly-ADP ribose polymerase (PARP) inhibitors are availabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef8bf3dd7a004dff78a0e401c4d9eed0
https://pubmed.ncbi.nlm.nih.gov/33423551
https://pubmed.ncbi.nlm.nih.gov/33423551